Adaptive Biotechnologies

Adaptive Biotechnologies is a biotechnology company focused on immune-driven medicine. It harnesses the adaptive immune system as a natural diagnostic and therapeutic tool to improve how diseases are detected, monitored, and treated.

Key points from the website:

• Uses the adaptive immune system as a rich source of information about health and disease.
• Translates immune system genetics into actionable data for clinicians and biopharma partners.
• Aims to power a paradigm shift in medicine by decoding and deploying the adaptive immune system.

Immune Medicine Platform

Adaptive's Immune Medicine Platform decodes immune receptor genetics at scale and turns them into data that can be used in research, clinical care, and drug development.

The platform enables:

• Highly sensitive measurement of measurable residual disease (MRD) in lymphoid malignancies.
• Generation of rich immune receptor data to inform clinical trials and the development of new medicines.
• A data-driven product-development process that uses the adaptive immune system as its "source code."

Key focus areas

Measurable Residual Disease (MRD)

• Development and delivery of clonoSEQ®, an NGS-based MRD test for lymphoid cancers.
• Support for both clinical practice (patient care) and drug trials (biopharma services).

Immune Medicine and Biopharma Partnerships

• Collaboration with biopharma companies to integrate immune receptor and MRD data into clinical trials.
• Use of immune-driven insights to support the development and evaluation of transformative medicines.

Who Adaptive serves

• Clinicians and cancer centers caring for patients with lymphoid malignancies.
• Biopharma companies running clinical trials and seeking sensitive MRD endpoints and immune receptor insights.
• Patients with blood cancers who may benefit from more precise disease detection and monitoring.

Adaptive's website provides a contact form with routing to several departments, including:

• Research inquiries
• Client services
• Technical support
• Business development
• Media relations
• Investor relations

When you submit the form, your email address is used to respond to your inquiry and is governed by Adaptive's Privacy Policy.

Phone numbers

Corporate

• Phone: (206) 659-0067
• Fax: (206) 659-0667

Media relations

• Phone: (206) 279-2423

Clinical diagnostic customer support

• Phone: (888) 552-8988
• Fax: (866) 623-4408

For clinical product inquiries related to clonoSEQ®, the site directs users to connect via the dedicated clonoSEQ channels.

Locations

Seattle, Washington – Corporate Headquarters and Laboratory

• Facility type: Corporate headquarters; CLIA- and CAP-certified laboratory
• Address: 1165 Eastlake Ave E, Seattle, WA 98109

Bothell, Washington – Manufacturing and Operations

• Facility type: Manufacturing and QC, Equipment Engineering, Warehouse
• Address: 19910 N Creek Pkwy, Bothell, WA 98011

South San Francisco, California – Cellular Immunology and R&D Laboratory

• Facility type: Cellular Immunology, R&D Laboratory
• Address: 1140 Veterans Blvd., Ste. 100, South San Francisco, CA 94080

Careers and job applications

For job opportunities, Adaptive directs candidates to its career listings page on the website, where applications can be submitted online.

Lists Griffin, Kyle, Alliance, Eastlake, San Francisco, South San Francisco, Bothell, and Opportunity as a location. Names South, California, and Washington as a service area. Areas beyond these are not published.

Adaptive Biotechnologies posts legitimate job openings on its career listings page. Candidates are asked to apply directly through the careers site.

The site notes that malicious groups have posed as Adaptive employees using fraudulent email aliases to extend fake offers and request sensitive information. Adaptive emphasizes that:

• Authentic opportunities are listed on the official careers page.
• Candidates should apply directly via the Adaptive careers site.

Who Adaptive is looking for

The company seeks people who are:

• Curious and passionate about science and healthcare.
• Motivated to help advance immune-driven medicine and improve patient outcomes.
• Interested in "writing their own story" by contributing to meaningful change in medicine.

Benefits (as summarized from the site)

Healthcare

• Comprehensive medical, dental, and vision plans.
• Adaptive pays a high percentage (often around 90–100% of employee monthly premiums, as described on the site).

Commuter

• Support for green transportation.
• Company-paid ORCA card for Seattle staff.
• Commuter programs for work-related transit and parking at certain other offices.

Financial

• 401(k) plan with company match (traditional and Roth options available).
• Company-paid short- and long-term disability insurance.
• Life and AD&D insurance.

Mental wellness

• Access to counseling (phone or in-person).
• Legal and financial consultation for employees and immediate family members.

Time off

• Company-paid holidays.
• Sick and safe leave time.
• Generous vacation/paid time off plans for full-time employees.

Parental leave

• Adaptive-paid parental leave for new parents, in addition to short-term disability and the ability to use sick and vacation time, as described on the site.

Specific details can vary by role, location, and time; candidates should always refer to the latest information in job postings and HR materials.

Culture and core values

Adaptive emphasizes a people-centric culture designed to help employees ("Adapters") succeed and thrive.

Core values highlighted on the site include:

• Innovate fearlessly – Push boundaries and think boldly.
• Follow True North – Show integrity and do the right thing.
• Work together – Care about the success of colleagues, partners, and customers.
• Debate openly – Value discussion and diverse points of view.
• Make it happen – Demonstrate ownership and accountability.
• Have fun – Enjoy the work and environment.

Employee Resource Groups (ERGs)

Adaptive hosts several ERGs to support community and inclusion. Examples on the site include:

• Adaptive Pride
• Asian Pacific @ Adaptive
• Black Adapter Network (BAN)
• Environmental Sustainability @ Adaptive
• Veterans and Military @ Adaptive
• Women @ Adaptive

ERGs are inclusive, and allies are welcome.

Locations relevant for careers

Adaptive lists several primary office and lab locations that also appear in job postings:

• Seattle, WA: Corporate headquarters; CLIA- and CAP-certified laboratory.
• Bothell, WA: Manufacturing, QC, equipment engineering, and warehouse.
• South San Francisco, CA: Cellular immunology and R&D laboratory.

Equal opportunity and accommodations

Adaptive states that it is an Affirmative Action and Equal Opportunity Employer. Qualified applicants receive consideration without regard to protected characteristics such as race, color, religion, sex, sexual orientation, gender identity, national origin, veteran status, or disability.

The site also:

• References required Equal Employment Opportunity posters.
• Provides a dedicated email address for candidates with disabilities who need reasonable accommodations to search for jobs or submit applications.

For the most current benefits, policies, and open roles, candidates should review the latest postings on Adaptive's careers page.

• Chad Robins – Chief Executive Officer, Co‑founder, Chairman of the Board
• Julie Rubinstein – President and Chief Operating Officer
• Kyle Piskel – Chief Financial Officer
• Sharon Benzeno, PhD – Chief Commercial Officer, Immune Medicine
• Susan Bobulsky – Chief Commercial Officer, MRD
• Francis Lo – Chief People Officer
• Mary Pat Lancelotta – Senior Vice President, MRD Biopharma

These roles reflect responsibilities across corporate leadership, operations, finance, commercial strategy for Immune Medicine and MRD, people and culture, and MRD-focused biopharma partnerships.

Board of Directors (as named on the site)

The Board of Directors section of the Adaptive Leadership page includes:

• Chad Robins – Chairman of the Board
• Peter Neupert – Board Member
• Michelle Griffin – Board Member (title summarized from page heading)
• Robert Hershberg, MD, PhD – Board Member
• Katey Owen, PhD – Board Member

The Board provides governance and strategic oversight to support Adaptive's mission to advance immune-driven medicine.

For the most current and complete list of leaders and directors, including any updates to titles or membership, refer to the Adaptive Leadership page on the Adaptive Biotechnologies website.

Adaptive Biotechnologies provides MRD (measurable residual disease) testing services to biopharma companies using the clonoSEQ® assay in clinical trials for lymphoid malignancies.

Because modern therapies often produce very deep responses, traditional response measures alone can make trials long and less sensitive to important differences. MRD testing offers an earlier, more sensitive readout of treatment effect.

How clonoSEQ supports clinical trials

According to Adaptive's website, clonoSEQ in biopharma trials enables:

• Early and precise read on efficacy by detecting low levels of residual disease.
• Highly sensitive and specific assessment of MRD.
• Quantitative results for disease burden.
• Identification of disease missed by other response measures.
• Use as a tool by leading drug developers worldwide.

MRD expertise and support

Adaptive offers:

• Experts in MRD-informed clinical trials.
• Support across the drug development lifecycle, including:
• Clinical trial design considerations.
• Post-hoc analyses.
• Global regulatory strategy input around MRD endpoints.
• Capabilities supported by extensive published evidence (hundreds of publications cited on the site).

Assay performance and sample flexibility

Key performance and workflow features described on the site include:

• Ability to detect one malignant cell among up to one million cells in certain settings.
• Standardized MRD results across global sites.
• Regulatory and quality attributes:
• CE-marked under the European Union's In Vitro Diagnostic Medical Device Regulation for certain B-cell malignancies.
• U.S. regulatory clearance for specific indications, with broader use as a CLIA-validated laboratory developed test (LDT).

• Flexible sample types and timepoints*:
• Fresh or frozen specimens.
• Cellular and circulating tumor DNA (ctDNA) samples.
• Multiple specimen types such as bone marrow, blood, plasma, and tissue.

*For disease- and study-specific specimen requirements, Adaptive directs users to detailed specimen guidelines.

Global clinical trial footprint

From the website, Adaptive's biopharma MRD services include:

• Partnerships with 50+ pharma companies.
• More than 180 active industry-sponsored clinical trials.
• Use of MRD as:
• A secondary endpoint in many studies.
• A primary endpoint in a significant number of active studies.
• Data that have supported regulatory approvals for multiple therapeutic modalities (e.g., CAR T therapies, bispecific T-cell engagers, monoclonal antibodies, BCL2 inhibitors).
• Experience supporting partners in Human Genetics Resources Administration of China (HGRAC) applications.

Use in routine clinical practice

The same clonoSEQ technology used in trials is also widely used in routine clinical care, including:

• Inclusion in major clinical practice guidelines (e.g., NCCN Guidelines® as cited on the site).
• Adoption by all 33 NCCN cancer centers and many additional centers.

How biopharma partners engage with Adaptive

• Biopharma partners can work with Adaptive to design MRD-informed trials, implement MRD testing within multicenter or global studies, and perform analyses that incorporate MRD endpoints.
• Contact details for MRD Biopharma Services are provided on Adaptive's website, including a dedicated Alliance Management email address for current clients.

For the most current, study-specific, and regulatory details, biopharma sponsors should refer to Adaptive's official biopharma materials and contacts.

clonoSEQ® is a measurable residual disease (MRD) test for certain lymphoid cancers. It uses next-generation sequencing (NGS) to detect and track small numbers of cancer cells that may remain during and after treatment and that can contribute to disease recurrence.

The test is designed to provide deep detection and actionable insights to help inform treatment decisions.

How clonoSEQ works

1. Baseline sequencing

• Performed once using a high–tumor burden sample.
• Identifies and quantifies patient-specific DNA sequences associated with malignant B or T cells.
• Can detect as few as one cancer cell among 1,000,000 healthy cells (10^-6), depending on sample quality and other factors described in Adaptive's technical materials.

2. Follow-up MRD testing

• Conducted at multiple timepoints during and after treatment.
• Tracks the previously identified DNA sequences over time.
• Helps reveal changes in residual cancer cell levels and provides insight into treatment response and potential relapse.

Indications and validation (as described on the site)

According to Adaptive's website, clonoSEQ is:

• FDA-cleared in:
• Multiple myeloma (MM)
• Chronic lymphocytic leukemia (CLL)
• Acute lymphoblastic leukemia (ALL)

• CLIA-validated in:
• Diffuse large B-cell lymphoma (DLBCL)
• Mantle cell lymphoma (MCL)
• Other lymphoid cancers*

*For full, up-to-date FDA-cleared indications, limitations, and performance characteristics, refer to the technical summary at clonoSEQ.com/technical-summary and associated labeling.

Clinical adoption and guidelines

From the website:

• Broad clinical use
• Ordered by thousands of oncologists.
• Used at leading academic and community centers, including all 33 National Comprehensive Cancer Network (NCCN) cancer centers.

• Guideline inclusion
• NGS-based MRD testing is incorporated in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for ALL, CLL, DLBCL, MCL, and multiple myeloma.

• Extensively studied
• Supported by hundreds of peer-reviewed publications across these disease areas, as referenced on Adaptive's site.

Reimbursement and patient cost (as stated on the site)

• The website notes that approximately 300 million lives are covered by Medicare and major private insurers for clonoSEQ testing in certain indications.
• It also states that more than 90% of clonoSEQ patients pay $0 out of pocket for testing.

Coverage and patient responsibility depend on individual insurance plans, indications, and other factors; refer to Adaptive's materials and your insurer for current details.

Role in patient care

clonoSEQ can be used to:

• Assess depth of response to therapy.
• Monitor disease burden over time.
• Help detect potential relapse earlier than standard imaging in certain settings.
• Provide information that may support more individualized treatment decisions, as described in Adaptive's educational examples and patient stories.

Where to learn more

• Detailed clinical information, ordering guidance, and the full technical summary are available at clonoSEQ.com.
• Clinicians should consult official labeling, guidelines, and Adaptive's technical documentation for the most current and comprehensive information on clonoSEQ indications, performance, and limitations.

Ask anyway — the agent will say plainly that it is not published rather than guess.